Clinical Trial Update: Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating cabozantinib in combination with nivolumab for metastatic castration-resistant prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• cabozantinib (cabozantinib)
• nivolumab (nivolumab)

Snippet

Sponsor: Rana McKay, MD | Conditions: Castration-resistant Prostate Cancer, Metastatic Cancer | Phase 2 | Status: RECRUITING